Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Stopped early · Phase 1

Conditions studied: Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma

In brief

This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.

Key facts

Study ID

NCT04173338

Run by

Augusta University

People needed

9

Starts

2020-01-23

Expected to finish

2022-03-28

Last updated by the study team

2022-06-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced NSCLC, urothelial cancer or malignant mesothelioma.
• 18 years or older.
• At least one prior chemotherapy before entering in this trial.
• Not pregnant or breastfeeding.

You may not qualify if…

• Prior treatment with cabozantinib.
• Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study).
• History of bleeding disorder/bleeding history within 12 weeks before first study treatment dose.

Where it is running

• Augusta University Georgia Cancer Center — Augusta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.